Siemens Healthineers launches Novagnost assay for Zika virus

Siemens Healthineers has announced the launch of its new Novagnost Zika virus IgM micro-capture assay in territories outside the US.

The assay is capable of detecting the Zika virus during the acute phase of infection, which occurs a few days after the onset of symptoms. It can be performed using the BEP III1 and BEP 2000 Advance systems, and is validated for use on plasma and serum.

Its user-friendly design utilises the same dilution and reagents as other Novagnost assays and, when used in conjunction with the real-time molecular Versant Zika RNA 1.0 assay, means laboratories now have tests both for immunoassay and molecular detection.

The spread of the Zika virus remains an important global public health concern, with medical professionals and scientists placing an increased focus on detecting the virus during the acute phase of infection.

Franz Walt, president for laboratory diagnostics at Siemens Healthineers, said: "With the introduction of the Novagnost Zika virus IgM micro-capture assay, Siemens Healthineers completes laboratories' virus testing menu by delivering assays for both immunoassay and molecular detection."

With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.